Morgan Stanley upgraded Abivax (ABVX) to Overweight from Equal Weight with a price target of $71, up from $12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Why Is Abivax Stock (ABVX) Up 490% Today?
- Abivax price target raised to $101 from $50 at Guggenheim
- Abivax price target raised to $70 from $42 at Piper Sandler
- Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
- Abivax price target raised to $95 from $33 at Citizens JMP